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Abstract: More than 200 generic drugs were screened to identify the inhibitory activity  
on melanogenesis in mouse B16 melanoma cells. Cinnarizine and trazodone were 
identified as melanogenesis inhibitors. The inhibitory effects of the two drugs on cell 
survival, melanogenesis, and tyrosinase activity were investigated. The results showed that 
both cinnarizine and trazodone inhibited melanogenesis in B16 cells by a dose-dependent 
manner at the non-cytotoxic concentrations. Based on the results of the present study, 
seeking new melanogenesis inhibitors from generic drugs is an alternative approach to 
developing new depigmenting agents in cosmeceuticals. Moreover, cinnarizine and 
trazodone were proven to be good candidates as skin-whitening agents for treatment of 
skin hyperpigmentation. 
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1. Introduction 
Human skin color is mainly determined by pigment melanin, which is produced by dermal 
melanocytes through a melanin synthesis process, melanogenesis. Melanogenesis occurs in a special 
organelle, melanosome, in melanocytes and is initiated by a key enzyme, tyrosinase [1]. The enzyme 
catalyses the first step of oxidation of L-tyrosine or L-DOPA (L-3,4-dihydroxyphenylalanine) to 
dopaquinone, which would form melanin in advance. This is a rate-limiting step in melanin synthesis 
because the remainder of the reaction sequence can proceed spontaneously at a physiological pH value. 
Although melanin mainly plays a photoprotective role, the accumulation of abnormal amounts of 
melanin in different parts of the skin, which results in pigmented patches of skin, might become an 
esthetic problem. Therefore, several studies have focused on the inhibition of tyrosinase activity and 
the prevention of abnormal pigmentation [2–4]. 
Recently, a huge number of melanogenesis inhibitors were discovered due to a great improvement 
on knowledge about the regulation of melanogenesis [5–7]. However, few of them have been given 
approval in cosmeceutical ingredients due to a lack of clinical trials to demonstrate the safety of the 
newly discovered drugs on human usage. In fact, both time and cost for the clinical trials on safety are 
usually longer and higher than those for the trials on skin-whitening efficiency. Based on the limitation 
of safe usage for new-drug development, we try to find new skin depigmenting agents from generic 
drugs which have been used in hospitals for therapy on other diseases. These drugs have been 
demonstrated to be safe and approved for human usage. As long as the generic drugs are proven to 
possess depigmenting activity, they could be used in cosmeceuticals very soon without the necessity 
for clinical trials on safety. 
In the preliminary study, we selected more than 200 generic drugs to search new depigmenting agents. 
The criteria of the selected drugs include being approved by The Food and Drug Administration of 
Taiwan, on the paid-drugs list by The Bureau of National Health Insurance of Taiwan, and in the form of 
pill. The list of the drugs is shown in Table 1. Six drugs, including aspirin, cinnarizine (Figure 1(A)), 
danazol, homochlorcyclizine, miconazole, and trazodone (Figure 1(B)), were identified as melanogenesis 
inhibitors. Among them, aspirin [8] and miconazole [9] have been reported with the anti-melanogenesis 
activity in B16 cells in the literatures. We also have studied the melanogenesis inhibition by danazol [10] 
and homochlorcyclizine [11]. In the present study, we continued to investigate the melanogenesis 
inhibition by cinnarizine and trazodone in B16 cells. 
Figure 1. The chemical structures of cinnarizine (A) and trazodone (B). 
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Table 1. The generic drugs screened in this study. In the table, some selected drugs, which 
are the same generic drug but produced by different company with a different brand or 
commercial name, are listed as the same drug name. The positively screened drugs are 
shown in a bold font. 
The generic drugs screened in this study 
Acarbose Colchicine  Fexofenadine  Meloxicam  Pertiazem 
Acemetacin Cortisone    Fluconazole Mepenzolate  Phenytoin 
Acetaminophen Coumadin  Fludiazepam  Mephenoxalone  Pioglitazone 
Aldioxa Cyprohetadine Flunarizine Mequitazine  Piracetam 
Allopurinol Dacoton  Fluoxetine  Metformin  Polaramine 
Alusa  Danazol  Formoterol   Methimazole  Ranitidine  
Ambroxol Dexamethasone  Furosemide  Methocarbamol  Rifater 
Amlodipine Dexchlorpheniramine  Gemfibrozil Methotrexate  Ritampin 
Amoxicillin Diclofenac  potassium  Ginkgoflavon  Metoclopramide  Rosiglitazone 
Apresoline Dicloxacillin  Glibenclamide  Metronidazole  Selegiline 
Aspirin  Dihydroergotoxine   Glimepiride  Mexiletine   Sennoside 
Atenolol Dimethicone  Glipizide  Miconazole  Silymarin 
Baclofen Diovan  Glucosamine   Minocycline  Simvastatin 
Benzbromarone Diphenidol  Homochlorcyclizine Mosapride Songora   
Benzonatate Dipyridamole  Hydralazine Nalidixic  acid  Souriree 
Bethanechol Ditiazem  Hydroxychloroquine Naproxen  Spironolaotone 
Biorix Domperidol  Hydroxyzine Narcaricin Strocain 
Bisacodyl Doxazosin  Hyoscyamine  Neomycin  Sulfinpyrazone 
Bismuth Doxycycline  Ibuprofen Nicardipine  Sulindac 
Bisoprolol Doxymycin  Imdur  Nicergoline Tamoxifen 
Bromhexine Elistin  Indapamide Nicorandil  Terazosin 
Captopril Enalapril    Indomethanoin Nifedipine  Theophyllin 
Carvedilol Entacapone  Iodopropylidene   Nifuroxazide  Thyroxine 
Cefadroxil Enzdase  Isoniazid  Nimodipine Trazodone 
Celecoxib Eprazine  Isosorbide   Nitroxoline  Trihexyphenidy
Cephalexin Ergonovine  Ketoconazole Nystatin    Trimethoprim 
Cetirizine Erythromycin  Ketorolac Ofloxacin  Tsurupinate 
Cimetidine Escitalopram    Levamisole  Oxatomide  Uliden 
Cinnarizine  Ethambutol Loperamide  Pantoprazole  Ultracet 
Ciprofloxacin Famotidine  Loratadine  Pecolin  Valproic  acid 
Clindamycin Felodipine  Mapirocin   Pentoxifylline  Verapamil 
Clonazepam Fenoterol  Mebendazole  Peptidin  Warfarin 
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2. Results and Discussion 
We evaluated the cytotoxicity of cinnarizine and trazodone to mouse B16 melanoma cells before 
the depigmenting assay. The cells were treated with different concentrations of the drugs and then  
the cell survival was determined by the MTT method (Figure 2). Trazodone showed significant 
cytotoxicity at 140 µM, while cinnarizine did not exhibit any cytotoxicity less than 20 µM. In order to 
avoid the misinterpretation of depigmenting results from killing melanocytes but not from inhibiting 
melanogenesis by the drug, we used 70 µM and 20 µM as a maximal concentration for trazodone and 
cinnarizine, respectively, in the following experiments. 
Figure 2. Effects of cinnarizine (A) and trazodone (B) on cell survival in B16 cells. The 
cells were cultivated for 1 d and then stimulated with 100 µM of IBMX for 2 d with 
various concentrations of the tested drugs. The cell survival was determined by the MTT 
method. Averaged data (n = 3) are presented with error bars indicating SD. A value of  
p < 0.001 (*), obtained with a Student’s t-test by comparing the data with that of control, 
was considered statistically significant. 
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To study the effects of cinnarizine and trazodone on melanogenesis in B16 cells, the cells were 
treated with the drugs and the melanin contents in the treated cells were directly monitored by 
Fontana-Masson stain of the cells (Figure 3). In the present study, we used IBMX, which is an elevator 
of cellular cAMP level, to stimulate melanogenesis in B16 cells. Two melanogenesis inhibitors, arbutin 
and danazol, were used as positive standards [10]. The melanin content in the cells was increased after 
IBMX treatment and the increased in melanin content was reduced by both arbutin and danazol 
treatments. All cinnarizine and trazodone treatments also significantly decreased the melanin content of 
the treated cells compared with that of the IBMX-stimulated cells. The melanin content of the treated 
cells was also determined by a photometric method, which detects the melanin content in cells via the 
absorption of the NaOH-dissolved melanin at 490 nm (Figure 4). The resulting profile was similar to 
that obtained with Fontana-Masson stain and dose-dependent melanogenesis inhibitions by the two 
drugs were clearly observed. Int. J. Mol. Sci. 2011, 12                 
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Figure 3. Fontana-masson stain of B16 cells treated with cinnarizine and trazodone. The 
cells were cultivated for 1 d and then stimulated with 100 µM of IBMX for 2 d with 
various concentrations of the tested drugs. The melanin content of the cells was determined 
by Fontana-Masson stain, as described in the experimental section. 
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Figure 4. Effects of cinnarizine (A) and trazodone (B) on melanogenesis in B16 cells. The 
cells were cultivated for 1 d and then stimulated with 100 µM of IBMX for 2 d with 
various concentrations of the tested drugs. The melanin content of the cells was determined 
by spectrometry, as described in the experimental section. Averaged data (n = 3) are 
presented with error bars indicating SD. A value of p < 0.001 (*), obtained with a Student’s 
t-test by comparing the data with those for the IBMX-stimulated control, was considered 
statistically significant. 
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Because tyrosinase plays a key role in melanogenesis, we then investigated the effects of the two 
drugs on the activity of this enzyme using a photometric method (Figure 5). Unexpectedly, neither 
cinnarizine nor trazodone directly inhibited tyrosinase activity, while kojic acid, a standard of tyrosinase 
inhibitor, showed strong inhibition on the enzyme activity. Therefore, melanogenesis inhibition by 
cinnarizine and trazodone in B16 cells apparently did not occur via direct inhibition on tyrosinase 
activity and the two drugs are not tyrosinase inhibitors. The detail molecular mechanism of the 
melanogenesis inhibition by cinnarizine and trazodone needs to be resolved in a further study.  
A previous study has reported that many cytokines and growth factors play important regulatory 
roles in melanogenesis [12]. α-Melanocyte stimulating hormone (α-MSH) is the most well-studied 
hormone. This hormone binds to its receptor, melanocortin receptor 1 (MC1R), on the membrane of 
melanocytes and stimulates melanogenesis via the GPCR (G protein-coupled receptor)-cAMP-MITF 
(microphthalmia-associated transcription factor) pathway where the melanogenesis-related enzymes, 
including tyrosinase and tyrosinase-related proteins 1 and 2 (TRP1 and TRP2) are upregulated. 
Accordingly, agents blocking the signal pathway would also exhibit depigmentation against 
melanocytes [5–11]. It is very interesting to note that the functions of four discovered melanogenesis 
inhibitors are related to hormone regulation. Both cinnarizine and homochlorcyclizine are histamine 
receptor antagonists. Trazodone is a serotonin receptor antagonist and danazol is a synthetic testosterone. 
These four generic drugs were proven to inhibit IBMX or α-MSH-stimulated melanogenesis in B16  
cells. In our previous studies, we have demonstrated that homochlorcyclizine and danazol inhibited   Int. J. Mol. Sci. 2011, 12                 
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α-MSH-stimulated melanogenesis in B16 cells, but not via antagonism toward the histamine receptor 
or androgen receptor, respectively [10,11]. Until now, how these generic drugs affect the α-MSH 
signal pathway and then inhibit melanogenesis remains unclear and needs to be studied in the future. In 
addition, despite these newly discovered drugs that showed potent antimelanogenic activity, more 
clinical assays should be performed before development as depigmenting agents and the related in vivo 
assays that were under out current work. 
Figure 5. Effects of cinnarizine (A) and trazodone (B) on murine tyrosinase activity. 
Tyrosinase activity was determined by spectrometry, using L-DOPA as a substrate, as 
described in the experimental section. B16 cells were cultivated for 5 d and lysed to obtain a 
crude tyrosinase extract. The cell-free tyrosinase activity was determined by directly mixing 
the crude tyrosinase, L-DOPA, and various concentrations of cinnarizine and trazodone. 
Averaged data (n = 3) are presented with error bars indicating SD. A value of p < 0.001 (*), 
obtained with a Student’s t-test by comparing the data with that of control, was considered 
statistically significant. 
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3. Experimental Section  
3.1. Materials 
All generic drug tablets used in this study are listed in Table 1 and were obtained as gifts from  
Pin-Chin Tsai in Department of Pharmacy, E-Da Hospital, Kaohsiung, Taiwan. Arbutin, 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), L-DOPA, dimethyl sulfoxide (DMSO), 
trypsin/EDTA, synthetic melanin, 3-isobutyl-1-methylxanthin (IBMX), cinnarizine and trazodone were 
purchased from Sigma (St. Louis, MO, USA). All other chemicals were obtained from Tokyo 
Chemical Industry (Tokyo, Japan). 
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3.2. Cell Cultures and Drug Treatments 
Mouse B16 melanoma cells (4A5) were obtained from the Bioresources Collection and Research 
Center (BCRC, Food Industry Research and Development Institute, Hsinchu, Taiwan). The cells were 
cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% (v/v) fetal bovine 
serum at 37 °C in a humidified, CO2-controlled (5%) incubator. The cells were seeded at an 
appropriate cell density in a 24-well plate. After 1 d of incubation, the cells were treated with various 
concentrations of the drugs in the absence or presence of a stimulation agent (100 µM of IBMX) for 
another 2 d. Thereafter, the cells were harvested and used for various assays. 
3.3. Measurements of Cell Viability 
MTT assay was performed to examine the viability of cells [7]. Afterwards, the cells were 
incubated with the samples for 48 h, the culture medium was removed and replaced with 1 mg/mL 
MTT solution dissolved in phosphate-buffered saline (PBS) and incubated for an additional 2 h. The 
MTT solution was then removed and DMSO was added, following which the absorbance of the 
dissolved formazan crystals was determined at 570 nm by a spectrophotometer. 
3.4. Fontana-Masson Stain 
At the end of cell culture, the cells were harvested and washed twice with PBS. Fontana-Masson 
stain of the cells was conducted by a Fontana-Masson stain Kit (ScyTek Lab., Logan, UT, USA) 
according to the manufacturer’s instructions. The Kit is used for the visualization of melanin in cells, 
where cell nuclei, cytoplasm and melanin would display red, light pink, and black, respectively, after 
staining. The staining cells were photographed under a phase-contrast microscopy equipped with a 
digital camera. 
3.5. Determination of Melanin Content 
The assay of evaluation of melanin content in B16 cells was according to our previous paper [7]. At 
the end of cell cultivation, the cells were harvested and washed twice with PBS. The pelleted cells 
were lysed in repeated frozen in lysis buffer containing 20 mM sodium phosphate (pH 6.8) and 1% 
Triton X-100. After centrifugation at 15,000 × g for 15 min, the melanin pellets were dissolved in 1 N 
NaOH containing 20% DMSO for 1 h at 95 °C. The melanin content was measured by the absorbance 
at 490 nm. 
3.6. Measurements of Tyrosinase Activity 
Murine tyrosinase activity was examined by measuring the rate of oxidation of L-DOPA [7]. A 
source of crude cellular tyrosinase was obtained by homogenizing B16 cells in 20 mM sodium 
phosphate (pH 6.8), 1% Triton X-100, and 1 mM PMSF at 4 °C with 30 repeated strokes in a Dounce 
homogenizer. Detergent was used to release the membrane-bound tyrosinase from the melanosomes. 
The lysates were centrifuged at 15,000 rpm for 15 min to obtain the supernatant as the source of the 
crude tyrosinase extract. The protein content in the supernatant was determined using a Bradford assay Int. J. Mol. Sci. 2011, 12                 
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with BSA as the protein standard. Tyrosinase activity was then determined as follows: 1 mL of the 
reaction mixture contained 50 mM of phosphate buffer (pH 6.8), 2.5 mM of L-DOPA, the tested drug, 
and 500 µg of the supernatant protein, and was incubated at 37 °C for 15 min, following which the 
dopachrome formation was monitored by measuring absorbance at a wavelength of 475 nm. 
3.7. Statistical Analysis 
All the data in the present study were obtained as averages of experiments that were performed in 
triplicate and are expressed as means ± S.D. Statistical analysis was performed by the Student’s t test. 
A value of p < 0.001 was considered to be statistically significant. 
4. Conclusions  
In conclusion, our results clearly demonstrated that searching new melanogenesis inhibitors from 
generic drugs is an alternative approach to develop new depigmenting agents in cosmeceuticals. From 
the results of the present study, cinnarizine and trazodone may be useful as candidates as   
skin-whitening agents for the treatment of skin hyperpigmentation. 
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